接受腹腔內化學治療卵巢癌患者的症狀困擾與照護

Nursing Care for Ovarian Cancer Patients with Intraperitoneal Chemotherapy

盧玉嬴(Yu-Ying Lu) ； 周如芬(Ju-Fen Chou) ； 曹麗英(Lee-Ing Tsao) ； 梁淑媛(Shu-Yuan Liang) ； 吳淑芳(Shu-Fang Wu)

《護理雜誌》 62卷1期 (2015/02) Pp. 87-91

https://doi.org/10.6224/JN.62.1.87

摘要

卵巢癌素有「沉默殺手」之稱，高居女性癌症死亡率之首位。卵巢癌標準治療為減積手術輔以鉑藥物之化學治療，以期延長病人的存活期。美國婦科腫瘤學會之臨床研究顯示接受減積手術後輔以靜脈合併腹腔內化學治療之卵巢癌個案其平均生存率以及平均無惡化生存時間均高於僅接受靜脈化學治療之個案，成為治療卵巢癌一項新的選擇方式。然而腹腔內化學治療費用較高、副作用大加上導管相關的併發症，成為此項治療的一大挑戰。本文提供臨床照護人員對於腹腔內化學治療可能產生的毒性副作用及併發症之認識，作為照護腹腔內化學治療患者之參考指引。

關鍵字

卵巢癌 ； 減積手術 ； 腹腔內化學治療

並列摘要

Ovarian cancer, known as a ＂silent killer＂, is the leading cause of gynecologic cancer death. Standard treatments for ovarian cancer are debulking surgery combined with platinum chemotherapy drugs to prolong the survival of patients. According to clinical trials run by the American Society of Gynecologic Oncology, patients who received intraperitoneal (IP) chemotherapy survived longer on average than patients who received intravenous chemotherapy alone. Thus, intraperitoneal chemotherapy is a new potential approach for treating ovarian cancer patients. However, the toxicities and undesirable complications of IP chemotherapy are the major challenges of this treatment approach. This article helps nurses recognize the toxicities and complications of IP chemotherapy and may be used as reference for future revisions to patient care guidelines.

並列關鍵字

ovarian cancer ； debulking ； intraperitoneal chemotherapy

參考文獻

洪敏瑛、邱文姿、陳淑娟、戴仕卿、蕭逸美（2011）．癌症病人嗜中性白血球低下臨床照護指引．腫瘤護理雜誌，11，41–60。[Hong, M. Y., Chiu, W. T., Chen, S. C., Tai, S. C., & Hsiao, Y. M. (2011). Clinical practice guideline on neutropenia in cancer patients. The Journal of Oncology Nursing, 11, 41–60.]

徐昌鴻（2009）．化學治療藥物所引起的神經病變．腫瘤護理雜誌，9（1），1–12。[Hsu, C. H. (2009). Neurotoxicity of chemotherapeutic agents. The Journal of Oncology Nursing, 9(1), 1–12.]

李耀泰、陳福民、朱益志、郭宗正（2007）．表皮性卵巢癌之腹腔內化學治療．中華民國婦癌醫學雜誌，2，32–37。[Li, Y. T., Chen, F. M., Chu, Y. C., & Kuo, T. C. (2007). Introperitoneal chemotheraphy for ovarian cancer. Journal of Gynecologic Oncology, 2, 32–37.]

Almadrones, L. (2007). Evidence-based research for intraperitoneal chemotherapy in epithelial ovarian cancer. Clinical Journal of Oncology Nursing, 11, 211–216.

Anderson, N. J., & Hacker, E. D. (2008). Fatigue in women receiving intraperitoneal chemotherapy for ovarian cancer: A review of contributing factors. Clinical Journal of Oncology Nursing, 12(3), 445–454.